Michael Hudecek
Overview
Explore the profile of Michael Hudecek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
5387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dragon A, Bonifacius A, Lienenklaus S, Verboom M, Gerhards J, Ius F, et al.
Mol Ther
. 2025 Jan;
33(3):1031-1047.
PMID: 39799394
Antibody-mediated rejection (AMR) remains a major complication after solid organ transplantation (SOT). Current treatment options are inefficient and result in drastic impairment of the general immunity. To selectively eliminate responsible...
2.
Fleischer A, Kurth S, Duell J, Topp M, Strunz P, Mersi J, et al.
J Immunother Cancer
. 2025 Jan;
12(12.
PMID: 39794934
Background: Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative modality in the treatment of patients with cancer. However, it is increasingly evident that this therapeutic approach is...
3.
Jacobs J, Beekers I, Verkouter I, Richards L, Vegelien A, Bloemsma L, et al.
PLOS Digit Health
. 2025 Jan;
4(1):e0000464.
PMID: 39787064
Precision, or personalised medicine has advanced requirements for medical data management systems (MedDMSs). MedDMS for precision medicine should be able to process hundreds of parameters from multiple sites, be adaptable...
4.
Gehrke L, Goncalves V, Andrae D, Rasko T, Ho P, Einsele H, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769449
The successful application of CAR-T cells in the treatment of hematologic malignancies has fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell clinical trials, efforts are being made...
5.
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, et al.
J Immunotoxicol
. 2024 Dec;
21(sup1):S13-S28.
PMID: 39655500
The success of cellular immunotherapies such as chimeric antigen receptor (CAR) T cell therapy has led to their implementation as a revolutionary treatment option for cancer patients. However, the safe...
6.
Dinh-Le T, Escobar J, Poisson L, Adkins K, Jornet Culubret M, Scheller L, et al.
J Immunotoxicol
. 2024 Dec;
21(sup1):S29-S37.
PMID: 39655494
CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have shown success in clinical studies, with several CD19 CAR-T cell products now having been approved for market use. However, this cell therapy...
7.
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel S, Hudecek M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594822
Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well as intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell...
8.
Mestermann K, Garitano-Trojaola A, Hudecek M
BioDrugs
. 2024 Nov;
39(1):33-51.
PMID: 39589646
Chimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies. However, their efficacy in other hematological cancers, such as acute myeloid leukemia, and in...
9.
Navarro S, Moukheiber C, Inoges Sancho S, Ruiz Guillen M, Lopez-Diaz de Cerio A, Sanges C, et al.
Mol Ther
. 2024 Nov;
33(3):847-865.
PMID: 39533710
Chimeric antigen receptor (CAR)-T cell products, classified as Advanced Therapy Medicinal Products (ATMPs), have shown promising outcomes in cancer immunotherapy. The quality of raw and starting materials used in manufacturing...
10.
Bauser M, Einsele H, Loffler J, Hudecek M, Seif M
J Vis Exp
. 2024 Oct;
(212).
PMID: 39431788
Chimeric antigen receptor (CAR)-based cell therapies have shown impressive efficacy in the treatment of hematological malignancies. Recently, these therapies are being developed for infectious diseases, yet studies targeting fungal infections...